Camp4 Therapeutics (CAMP) Net Cash Flow (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Net Cash Flow of -$10.9 million for Q1 2026, down 131.36% sequentially from $34.8 million in Q4 2025, and up 25.77% YoY from -$8.7 million in Q1 2025.
Camp4 Therapeutics (CAMP) Net Cash Flow (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Net Cash Flow for 4 years, with the latest figure at -$10.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 25.77% year-over-year to -$10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.9 million (up 123.67% YoY) and the FY2025 annual result came in at $46.1 million, up 79.64% from the prior year.
- Net Cash Flow retreated to -$10.9 million in Q1 2026 per CAMP's latest filing, from $34.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $61.5 million in Q4 2024 and troughed at -$14.7 million in Q1 2025.
- A 4-year average of $4.9 million and a median of -$10.6 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 608.82% in 2024, then sank 43.37% in 2025.
- Over 4 years, Net Cash Flow stood at -$12.1 million in 2023, then jumped by 608.82% to $61.5 million in 2024, then plunged by 43.37% to $34.8 million in 2025, then tumbled by 131.36% to -$10.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$10.9 million, $34.8 million, and $36.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | -12.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.83 Mn |
| Jun 30, 2026 | -12.83 Mn |
| Mar 31, 2026 | -10.92 Mn |
| Mar 31, 2026 | -10.92 Mn |
| Dec 31, 2025 | 34.83 Mn |
| Dec 31, 2025 | 34.83 Mn |
| Sep 30, 2025 | 36.25 Mn |
| Sep 30, 2025 | 36.25 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | 61.51 Mn |
| Dec 31, 2024 | 61.51 Mn |
| Sep 30, 2024 | -10.08 Mn |
| Sep 30, 2024 | -10.08 Mn |
| Jun 30, 2024 | -14.41 Mn |
| Jun 30, 2024 | -14.41 Mn |
| Mar 31, 2024 | -11.36 Mn |
| Mar 31, 2024 | -11.36 Mn |